Evidence map›Paper›PMID 28689840›Full record

ReviewThe journal of allergy and clinical immunology. In practice

Severe Asthma Phenotypes - How Should They Guide Evaluation and Treatment?

Anne M Fitzpatrick, Wendy C Moore

2 registry-linked trialsAbstract readReview
In one paragraph

Review in The journal of allergy and clinical immunology. In practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04612556 unknown statusnot on this map

Efficacy of Mepolizumab in Patients With Late-onset Severe Eosinophilic Asthma and Fixed Obstruction

TypeobservationalSponsorAristotle University Of ThessalonikiRan2021 to 2025Enrolled45ConditionsAsthma, Eosinophilic, Severe Asthma, Late-Onset AsthmaArmsMepolizumab 100 MG [Nucala]
NCT05365841 unknown statusnot on this map

Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP). Can Shedding of Epithelial Barrier Proteins be Used as Biomarker in Severe Asthma With/Out CRSwNP Management?

TypeobservationalSponsorUniversity of CreteRan2022 to 2025Enrolled85ConditionsSevere Eosinophilic Asthma w/wo CRSwNPArmsMepolizumab 100 MG
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Asthma Phenotypes and Biomarkers.Respiratory care · 2025
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Biologics in severe asthma: the role of real-world evidence from registries.European respiratory review : an official journal of the European Respiratory Society · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anne M FitzpatrickDepartment of Pediatrics, Emory University, Atlanta, Ga.
Wendy C MooreSection on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC. Electronic address: wmoore@wakehealth.edu.

Funding

Genotype-Phenotype Interactions in Severe AsthmaR01HL069167 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BLEECKER, EUGENE ROLAND · 2001 to 2010
$5.5M
Longitudinal Phenomics and Genetics of Severe AsthmaU10HL109164 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BLEECKER, EUGENE ROLAND, MEYERS, DEBORAH A. · 2011 to 2016
$3.8M
NHLBI NIH HHS R01 HL069167NHLBI NIH HHS U10 HL109164
6 · The paper itself

Abstract

Although patients with "severe" asthma tend to be characterized by ongoing symptoms and airway inflammation despite treatment with high doses of inhaled and systemic corticosteroids, there is increasing recognition of marked phenotypic heterogeneity within affected patients. Although "precision medicine" approaches for patients with severe asthma are needed, there are many hurdles that must be overcome in daily practice. The National Heart, Lung and Blood Institute's Severe Asthma Research Program (SARP) has been at the forefront of phenotype discovery in severe asthma for the past decade. SARP, along with other international groups, has described clinical severe asthma phenotypes in both adults and children that can be evaluated in the clinical setting. Although these clinical phenotypes provide a good "starting point" for addressing disease heterogeneity in severe asthma in everyday practice, more efforts are needed to understand how these phenotypes relate to underlying disease mechanisms and pharmacological treatment responses. This review highlights the clinical asthma phenotypes identified to date, their associations with underlying endotypes and potential biomarkers, and remaining knowledge gaps that must be addressed before precision medicine can become a reality for patients with severe asthma.

Indexed as

AsthmaAnti-Asthmatic AgentsBiomarkersHumansPhenotypeAnti-Asthmatic AgentsBiomarkersBiomarkerCluster analysisEndotypePrecision medicineSARPSevere asthma phenotypes

Identifiers

PMID28689840
PMCPMC5541906

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.